Plenadren

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Patient Information leaflet Patient Information leaflet (PIL)
06-12-2022
Summary of Product characteristics Summary of Product characteristics (SPC)
06-12-2022
Public Assessment Report Public Assessment Report (PAR)
05-01-2017

Active ingredient:

хидрокортизон

Available from:

Takeda Pharmaceuticals International AG Ireland Branch

ATC code:

H02AB09

INN (International Name):

hydrocortisone

Therapeutic group:

Кортикостероиди за системна употреба

Therapeutic area:

Надбъбречна недостатъчност

Therapeutic indications:

Лечение на надбъбречната недостатъчност при възрастни.

Product summary:

Revision: 14

Authorization status:

упълномощен

Authorization date:

2011-11-03

Patient Information leaflet

                                23
Б. ЛИСТОВКА
24
ЛИСТОВКА: ИНФОРМАЦИЯ ЗА ПАЦИЕНТА
PLENADREN 5 MG ТАБЛЕТКИ С ИЗМЕНЕНО
ОСВОБОЖДАВАНЕ
PLENADREN 20 MG ТАБЛЕТКИ С ИЗМЕНЕНО
ОСВОБОЖДАВАНЕ
хидрокортизон (hydrocortisone)
ПРОЧЕТЕТЕ ВНИМАТЕЛНО ЦЯЛАТА ЛИСТОВКА
ПРЕДИ, ДА ЗАПОЧНЕТЕ ДА ПРИЕМАТЕ ТОВА
ЛЕКАРСТВО,
ТЪЙ КАТО ТЯ СЪДЪРЖА ВАЖНА ЗА ВАС
ИНФОРМАЦИЯ.
-
Запазете тази листовка. Може да се
наложи да я прочетете отново.
-
Ако имате някакви допълнителни
въпроси, попитайте Вашия лекар или
фармацевт.
-
Това лекарство е предписано лично на
Вас. Не го преотстъпвайте на други
хора. То може
да им навреди, независимо че
признаците на тяхното заболяване са
същите като Вашите.
-
Ако получите някакви нежелани
реакции, уведомете Вашия лекар или
фармацевт. Това
включва и всички възможни нежелани
реакции, неописани в тази листовка.
Вижте
точка 4.
КАКВО СЪДЪРЖА ТАЗИ ЛИСТОВКА
1.
Какво представлява Plenadren и за какво се
използва
2.
Какво трябва да знаете, преди да
приемете Plenadren
3.
Как да приемате Plenadren
4.
Възможни нежелани реакции
5.
Как да съхранявате Plenadren
6.
Съдържание на опаковката и
допълнителна информация
1.
КАКВО ПРЕДСТАВЛЯВА PLENADREN И ЗА КАКВО СЕ
ИЗПОЛЗВА
Plenadren съдържа вещество, наречено
хидрокор
                                
                                Read the complete document

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
2
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
Plenadren 5 mg таблетки с изменено
освобождаване
Plenadren 20 mg таблетки с изменено
освобождаване
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Plenadren 5 mg таблетки с изменено
освобождаване
Всяка таблетка с изменено
освобождаване съдържа 5 mg
хидрокортизон (hydrocortisone)
Plenadren 20 mg таблетки с изменено
освобождаване
Всяка таблетка с изменено
освобождаване съдържа 20 mg
хидрокортизон (hydrocortisone)
За пълния списък на помощните
вещества вижте точка 6.1.
3.
ЛЕКАРСТВЕНА ФОРМА
Таблетка с изменено освобождаване
Plenadren 5 mg таблетки с изменено
освобождаване
Таблетките са кръгли (с диаметър 8 mm),
изпъкнали и розови.
Plenadren 20 mg таблетки с изменено
освобождаване
Таблетките са кръгли (с диаметър 8 mm),
изпъкнали и бели.
4.
КЛИНИЧНИ ДАННИ
4.1
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ
Лечение на надбъбречна
недостатъчност при възрастни.
4.2
ДОЗИРОВКА И НАЧИН НА ПРИЛОЖЕНИЕ
Дозировка
Plenadren се прилага като поддържаща
терапия. Пероралните дози при
заместваща терапия
трябва да се индивидуализират в
зависимост от клиничния отговор.
Обичайната поддържаща
доза е 20 - 30 mg на ден, която се прилага
веднъж дневно сутрин. П
                                
                                Read the complete document

Similar products

Active ingredient хидрокортизон

хидрокортизон

ATC code H02AB09

H02AB09

Marketed by Takeda Pharmaceuticals International AG Ireland Branch

Takeda Pharmaceuticals International AG Ireland Branch

INN (International Name) hydrocortisone

hydrocortisone

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 06-12-2022
Summary of Product characteristics Summary of Product characteristics Spanish 06-12-2022
Public Assessment Report Public Assessment Report Spanish 05-01-2017
Patient Information leaflet Patient Information leaflet Czech 06-12-2022
Summary of Product characteristics Summary of Product characteristics Czech 06-12-2022
Public Assessment Report Public Assessment Report Czech 05-01-2017
Patient Information leaflet Patient Information leaflet Danish 06-12-2022
Summary of Product characteristics Summary of Product characteristics Danish 06-12-2022
Public Assessment Report Public Assessment Report Danish 05-01-2017
Patient Information leaflet Patient Information leaflet German 06-12-2022
Summary of Product characteristics Summary of Product characteristics German 06-12-2022
Public Assessment Report Public Assessment Report German 05-01-2017
Patient Information leaflet Patient Information leaflet Estonian 06-12-2022
Summary of Product characteristics Summary of Product characteristics Estonian 06-12-2022
Public Assessment Report Public Assessment Report Estonian 05-01-2017
Patient Information leaflet Patient Information leaflet Greek 06-12-2022
Summary of Product characteristics Summary of Product characteristics Greek 06-12-2022
Public Assessment Report Public Assessment Report Greek 05-01-2017
Patient Information leaflet Patient Information leaflet English 06-12-2022
Summary of Product characteristics Summary of Product characteristics English 06-12-2022
Public Assessment Report Public Assessment Report English 05-01-2017
Patient Information leaflet Patient Information leaflet French 06-12-2022
Summary of Product characteristics Summary of Product characteristics French 06-12-2022
Public Assessment Report Public Assessment Report French 05-01-2017
Patient Information leaflet Patient Information leaflet Italian 06-12-2022
Summary of Product characteristics Summary of Product characteristics Italian 06-12-2022
Public Assessment Report Public Assessment Report Italian 05-01-2017
Patient Information leaflet Patient Information leaflet Latvian 06-12-2022
Summary of Product characteristics Summary of Product characteristics Latvian 06-12-2022
Public Assessment Report Public Assessment Report Latvian 05-01-2017
Patient Information leaflet Patient Information leaflet Lithuanian 06-12-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 06-12-2022
Public Assessment Report Public Assessment Report Lithuanian 05-01-2017
Patient Information leaflet Patient Information leaflet Hungarian 06-12-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 06-12-2022
Public Assessment Report Public Assessment Report Hungarian 05-01-2017
Patient Information leaflet Patient Information leaflet Maltese 06-12-2022
Summary of Product characteristics Summary of Product characteristics Maltese 06-12-2022
Public Assessment Report Public Assessment Report Maltese 05-01-2017
Patient Information leaflet Patient Information leaflet Dutch 06-12-2022
Summary of Product characteristics Summary of Product characteristics Dutch 06-12-2022
Public Assessment Report Public Assessment Report Dutch 05-01-2017
Patient Information leaflet Patient Information leaflet Polish 06-12-2022
Summary of Product characteristics Summary of Product characteristics Polish 06-12-2022
Public Assessment Report Public Assessment Report Polish 05-01-2017
Patient Information leaflet Patient Information leaflet Portuguese 06-12-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 06-12-2022
Public Assessment Report Public Assessment Report Portuguese 05-01-2017
Patient Information leaflet Patient Information leaflet Romanian 06-12-2022
Summary of Product characteristics Summary of Product characteristics Romanian 06-12-2022
Public Assessment Report Public Assessment Report Romanian 05-01-2017
Patient Information leaflet Patient Information leaflet Slovak 06-12-2022
Summary of Product characteristics Summary of Product characteristics Slovak 06-12-2022
Public Assessment Report Public Assessment Report Slovak 05-01-2017
Patient Information leaflet Patient Information leaflet Slovenian 06-12-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 06-12-2022
Public Assessment Report Public Assessment Report Slovenian 05-01-2017
Patient Information leaflet Patient Information leaflet Finnish 06-12-2022
Summary of Product characteristics Summary of Product characteristics Finnish 06-12-2022
Public Assessment Report Public Assessment Report Finnish 05-01-2017
Patient Information leaflet Patient Information leaflet Swedish 06-12-2022
Summary of Product characteristics Summary of Product characteristics Swedish 06-12-2022
Public Assessment Report Public Assessment Report Swedish 05-01-2017
Patient Information leaflet Patient Information leaflet Norwegian 06-12-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 06-12-2022
Patient Information leaflet Patient Information leaflet Icelandic 06-12-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 06-12-2022
Patient Information leaflet Patient Information leaflet Croatian 06-12-2022
Summary of Product characteristics Summary of Product characteristics Croatian 06-12-2022
Public Assessment Report Public Assessment Report Croatian 05-01-2017

Search alerts related to this product

Alerts Plenadren хидрокортизон hydrocortisone

Plenadren хидрокортизон hydrocortisone

View documents history

Documents history Documents history

Plenadren